Pharmaceuticals

cbdMD

cbdMD, Inc. Lists on NYSE American

cbdMD released FY2025 9 Months Earnings on August 14 EST, with actual revenue of USD 14.47 M and EPS of USD -3.8471

cbdMD released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 4.607 M (forecast USD 5.303 M), actual EPS USD -0.2124 (forecast USD -0.16)

cbdMD Inc. Launches Herbal Oasis Social Beverage

Maxim Group Maintains Buy Rating on cbdMD and Adjusts Price Target

cbdMD Inc. Partners with Beverage South to Expand THC Bubble Water Distribution

cbdMD Inc. Reports Q2 2025 Revenue Growth of 4.3%

cbdMD released FY2025 Q2 earnings during market hours on May 15 (EST), actual revenue USD 4.749 M (forecast USD 5.142 M), actual EPS USD -1.9029 (forecast USD -1.6)

cbdMD released FY2025 Semi-Annual Earnings on May 15 During-Market EST, Actual Revenue: USD 9.863 M, Actual EPS: USD -3.6675

cbdMD to Report Q1 2025 Earnings with EPS Forecast at -0.36 USD

cbdMD, Inc. to Hold Conference Call to Discuss Q2 2025 Financial Results

cbdMD to Release FY2025 Q2 Earnings During Market Hours on May 15 (EST), Forecast Revenue USD 5.142 M, EPS USD -1.6

cbdMD, Inc. Receives Approval from UK Food Standards Agency for Its CBD Ingredient

CBDMD released FY2025 Q1 earnings on February 13 After-Market EST, actual revenue USD 5.113 M (forecast USD 5.187 M), actual EPS USD -1.7317 (forecast USD -2.96)

cbdMD Reports Q1 FY2025 Revenue of $5.1 Million with Net Income of $15,000

CBDMD released FY2024 Q4 earnings on December 18 After-Market EST, actual revenue USD 4.556 M (forecast USD 4.806 M), actual EPS USD -1.4204 (forecast USD -3.6)

CBDMD released FY2024 earnings on December 18 After-Market EST, actual revenue USD 19.48 M (forecast USD 19.73 M), actual EPS USD -14.32 (forecast USD -21.04)

cbdMD's Compliance Plan Accepted by NYSE

cbdMD's Compliance Plan Accepted by NYSE American

cbdMD, Inc. releases Q3 2024 financial report

SMX Security Matters

Treasure Gbl

Gulf Resources

Wheeler Real Estate

Dreamland

Irobot

Praxis Precision Medicines

AiRWA

DigitalBridge

Urgently

禮來

ROCHE HOLDINGS AG

羅氏(ADR)

阿斯利康

諾華制藥

諾和諾德公司

中外制藥(ADR)

UCB(ADR)

第一三共株式會社(ADR)

大塚制藥(ADR)

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap